TRIAL RESULTS · SIDE EFFECTS
Angiotensin II side effects
ANSWER
In 1 placebo-controlled trial with posted results, the most common side effects of Angiotensin II were Multi-organ failure 15.3% (placebo 14.6%), septic shock 11.0% (placebo 6.3%), atrial fibrillation 10.4% (placebo 10.1%). Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
3
with an arm on Angiotensin II, of 364 registered
Against placebo
1
placebo-controlled trials
People in those trials
163
on Angiotensin II · 158 on placebo
Read
2026-10-03
ClinicalTrials.gov
VS PLACEBO
Most common side effects, Angiotensin II beside placebo
Share of people with each side effect in 1 placebo-controlled trial with posted results: 163 people on Angiotensin II (all doses), 158 on placebo, same trials. Listed only when reported for at least half of the people on Angiotensin II. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
ALL TRIALS
The 100 most reported of 147 side effects reported
Every trial with posted results and an arm on Angiotensin II (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Angiotensin II | Placebo | Trials |
|---|---|---|---|---|
| Multi-organ failure | General disorders | 15.3% (25 of 163) | 14.6% | 1 |
| Septic shock | Infections and infestations | 11.0% (18 of 163) | 6.3% | 1 |
| Atrial fibrillation | Cardiac disorders | 10.4% (17 of 163) | 10.1% | 1 |
| Thrombocytopenia | Blood and lymphatic system disorders | 8.7% (16 of 183) | 6.3% | 2 |
| Hypokalaemia | Metabolism and nutrition disorders | 8.0% (13 of 163) | 6.3% | 1 |
| Hypotension | Vascular disorders | 8.0% (13 of 163) | 4.4% | 1 |
| thrombocytopenia | Blood and lymphatic system disorders | 65.0% (13 of 20) | - | 1 |
| tachycardia | Cardiac disorders | 60.0% (12 of 20) | - | 1 |
| Anaemia | Blood and lymphatic system disorders | 6.7% (11 of 163) | 5.7% | 1 |
| Delirium | Psychiatric disorders | 5.5% (9 of 163) | 0.6% | 1 |
| Hypertension | Vascular disorders | 5.5% (9 of 163) | 5.7% | 1 |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | 4.9% (8 of 163) | 5.1% | 1 |
| Acute kidney injury | Renal and urinary disorders | 4.9% (8 of 163) | 6.3% | 1 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 4.9% (8 of 163) | 7.0% | 1 |
| Cardiac arrest | Cardiac disorders | 4.3% (7 of 163) | 5.7% | 1 |
| Hypophosphataemia | Metabolism and nutrition disorders | 3.7% (6 of 163) | 7.0% | 1 |
| Agitation | Psychiatric disorders | 3.7% (6 of 163) | 5.1% | 1 |
| Bradycardia | Cardiac disorders | 3.7% (6 of 163) | 5.7% | 1 |
| Ventricular tachycardia | Cardiac disorders | 3.1% (5 of 163) | 1.9% | 1 |
| Peripheral ischaemia | Vascular disorders | 3.1% (5 of 163) | 1.9% | 1 |
| infection | Infections and infestations | 25.0% (5 of 20) | - | 1 |
| Sepsis | Infections and infestations | 1.8% (3 of 163) | 1.3% | 1 |
| Cardio-respiratory arrest | Cardiac disorders | 1.8% (3 of 163) | 3.2% | 1 |
| Deep vein thrombosis | Vascular disorders | 1.8% (3 of 163) | 0.0% | 1 |
| Shock | Vascular disorders | 1.8% (3 of 163) | 1.9% | 1 |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | 1.8% (3 of 163) | 3.2% | 1 |
| Pneumonia | Infections and infestations | 1.2% (2 of 163) | 1.9% | 1 |
| Failure to thrive | Metabolism and nutrition disorders | 1.2% (2 of 163) | 0.6% | 1 |
| Acute myocardial infarction | Cardiac disorders | 1.2% (2 of 163) | 1.3% | 1 |
| Cardiogenic shock | Cardiac disorders | 1.2% (2 of 163) | 2.5% | 1 |
| Tachycardia | Cardiac disorders | 1.2% (2 of 163) | 0.0% | 1 |
| Ventricular fibrillation | Cardiac disorders | 1.2% (2 of 163) | 0.0% | 1 |
| hyperglycemia | Endocrine disorders | 10.0% (2 of 20) | - | 1 |
| Abdominal abscess | Infections and infestations | 0.6% (1 of 163) | 0.0% | 1 |
| Abdominal infection | Infections and infestations | 0.6% (1 of 163) | 0.0% | 1 |
| Enterobacter bacteraemia | Infections and infestations | 0.6% (1 of 163) | 0.0% | 1 |
| Liver abscess | Infections and infestations | 0.6% (1 of 163) | 0.0% | 1 |
| Necrotising fasciitis | Infections and infestations | 0.6% (1 of 163) | 0.0% | 1 |
| Pulmonary sepsis | Infections and infestations | 0.6% (1 of 163) | 0.0% | 1 |
| Tracheobronchitis | Infections and infestations | 0.6% (1 of 163) | 0.0% | 1 |
| Hepatic cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.6% (1 of 163) | 0.0% | 1 |
| Pancreatic carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0.6% (1 of 163) | 0.0% | 1 |
| Metabolic acidosis | Metabolism and nutrition disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Mental status change | Psychiatric disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Brain hypoxia | Nervous system disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Brain injury | Nervous system disorders | 0.6% (1 of 163) | 1.3% | 1 |
| Cerebral infarction | Nervous system disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Depressed level of conciousness | Nervous system disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Hemiparesis | Nervous system disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Hypoxic-ischaemic encephalopathy | Nervous system disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Ischaemic stroke | Nervous system disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Toxic leukoencephalopathy | Nervous system disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Arrhythmia | Cardiac disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Atrioventricular block | Cardiac disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Cardiopulmonary failure | Cardiac disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Right ventricular dysfunction | Cardiac disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Supraventricular tachycardia | Cardiac disorders | 0.6% (1 of 163) | 2.5% | 1 |
| Distributive shock | Vascular disorders | 0.6% (1 of 163) | 2.5% | 1 |
| Shock haemorrhagic | Vascular disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Vasospasm | Vascular disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Acute pulmonary oedema | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Aspiration | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Bronchomalacia | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Pharyngeal haemorrhage | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.6% | 1 |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 1.9% | 1 |
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Respiratory arrest | Respiratory, thoracic and mediastinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Gastrointestinal mucosal exfoliation | Gastrointestinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Haematemesis | Gastrointestinal disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Intestinal ischaemia | Gastrointestinal disorders | 0.6% (1 of 163) | 1.9% | 1 |
| Hepatic failure | Hepatobiliary disorders | 0.6% (1 of 163) | 0.6% | 1 |
| Hepatic function abnormal | Hepatobiliary disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Hepatic vascular thrombosis | Hepatobiliary disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Liver disorder | Hepatobiliary disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Skin discolouration | Skin and subcutaneous tissue disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Skin necrosis | Skin and subcutaneous tissue disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Muscle necrosis | Musculoskeletal and connective tissue disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Renal failure | Renal and urinary disorders | 0.6% (1 of 163) | 0.6% | 1 |
| Renal impairment | Renal and urinary disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Device dislocation | General disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Pyrexia | General disorders | 0.6% (1 of 163) | 0.0% | 1 |
| Alanine aminotransferase increased | Investigations | 0.6% (1 of 163) | 0.0% | 1 |
| Blood lactic acid increased | Investigations | 0.6% (1 of 163) | 0.0% | 1 |
| Electrocardiogram ST segment elevation | Investigations | 0.6% (1 of 163) | 0.0% | 1 |
| Liver function test abnormal | Investigations | 0.6% (1 of 163) | 0.0% | 1 |
| Staphylococcus test positive | Investigations | 0.6% (1 of 163) | 0.0% | 1 |
| Gastrointestinal anastomotic leak | Injury, poisoning and procedural complications | 0.6% (1 of 163) | 0.0% | 1 |
| Gastrostomy tube site complication | Injury, poisoning and procedural complications | 0.6% (1 of 163) | 0.0% | 1 |
| deep vein thrombosis | Vascular disorders | 5.0% (1 of 20) | - | 1 |
| atrial fibrillation | Cardiac disorders | 5.0% (1 of 20) | - | 1 |
| worsening septic shock | General disorders | 5.0% (1 of 20) | - | 1 |
| cardiac arrest | Cardiac disorders | 5.0% (1 of 20) | - | 1 |
| Bacteraemia | Infections and infestations | 0.0% (0 of 163) | 0.6% | 1 |
| Cardiac valve vegetation | Infections and infestations | 0.0% (0 of 163) | 0.6% | 1 |
| Clostridium difficile colitis | Infections and infestations | 0.0% (0 of 163) | 0.6% | 1 |
| Clostridium difficile sepsis | Infections and infestations | 0.0% (0 of 163) | 0.6% | 1 |
| Peritonitis | Infections and infestations | 0.0% (0 of 163) | 0.6% | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
FDA LABEL
What the FDA label says
Giapreza NDA209360 · label of 2026-07-22 Regulator
The most common adverse reactions reported in greater than 10% of GIAPREZA treated patients were thromboembolic events.
ANGIOTENSIN II ANDA216966 · label of 2025-06-04 Regulator
The most common adverse reactions reported in greater than 10% in Angiotensin II treated patients were thromboembolic events.
QUESTIONS
Does angiotensin ii cause Multi-organ failure?
In 1 placebo-controlled trial with posted results, 15.3% of people on angiotensin ii reported Multi-organ failure, against 14.6% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does angiotensin ii cause septic shock?
In 1 placebo-controlled trial with posted results, 11.0% of people on angiotensin ii reported septic shock, against 6.3% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does angiotensin ii cause atrial fibrillation?
In 1 placebo-controlled trial with posted results, 10.4% of people on angiotensin ii reported atrial fibrillation, against 10.1% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does angiotensin ii cause thrombocytopenia?
In 1 placebo-controlled trial with posted results, 9.2% of people on angiotensin ii reported thrombocytopenia, against 6.3% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does angiotensin ii cause hypokalaemia?
In 1 placebo-controlled trial with posted results, 8.0% of people on angiotensin ii reported hypokalaemia, against 6.3% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
REGISTERED STUDIES
364 registered clinical trials of Angiotensin II
The 10 most recently updated are listed.
| NCT06746753 | Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock Status: NOT_YET_RECRUITING · Updated 2026-09-24 |
|---|---|
| NCT06539234 | Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II. Status: RECRUITING · Updated 2026-09-16 |
| NCT06693726 | Early Angiotensin II in the Emergency Department Status: RECRUITING · Updated 2026-09-02 |
| NCT07775846 | QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy Status: NOT_YET_RECRUITING · Updated 2026-08-20 |
| NCT04715568 | Secondhand Tobacco Smoke and Cardiovascular Disease Status: RECRUITING · Updated 2026-08-19 |
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease Status: RECRUITING · Updated 2026-08-19 |
| NCT06588686 | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Status: ACTIVE_NOT_RECRUITING · Updated 2026-08-17 |
| 2025-524783-38-00 | Spironolactone and SGLT2 inhibitor to Address Fontan circulatory failure and Enhance Resilience: The SAFER-Fontan trial Status: UNKNOWN · Updated 2026-08-14 |
| 2023-504597-37-00 | A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) Status: UNKNOWN · Updated 2026-08-12 |
| NCT06150560 | A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) Status: ENROLLING_BY_INVITATION · Updated 2026-08-11 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.